Background. The haemodynamic effects of oxytocin 5 u have been described previously, but still some authors attribute these effects to the delivery itself. We studied the haemodynamic effects of two repeated doses of oxytocin i.v. in 20 healthy women during spinal anaesthesia for Caesarean delivery.
Oxytocin is the first choice drug for enhancing uterine contraction after delivery. There are oxytocin receptors in the uterus, and receptors have also been located in mammary, endothelial, and central nervous tissue as well. 1 The effect of oxytocin on endothelial receptors produces a calcium-dependent vasodilatory effect via stimulation of the nitric oxide pathway. 1 The substantial haemodynamic effect of oxytocin 5 u i.v. in healthy pregnant patients during spinal anaesthesia for Caesarean section has previously been published. 2 -5 In this study, we present data on the haemodynamic effects of two consecutive bolus doses of i.v. oxytocin in healthy parturients during elective Caesarean section.
Methods
Data were obtained from a randomized controlled study of 80 pregnant women undergoing an elective Caesarean section. 6 The trial was approved by the Regional Committee for Medical Research Ethics of Southern Norway. The women gave written consent to participate in the study. All women had an arterial line inserted, and LidCOPlus (LiDCO, London, UK) was used for invasive monitoring of stroke volume (SV), cardiac output (CO), and systemic vascular resistance (SVR). 7 8 This monitor performs a beat-by-beat analysis of the arterial pressure wave to determine SV and other haemodynamic variables which are stored in the computer. Women were given spinal anaesthesia with isobaric bupivacaine (7 or 10 mg) and sufentanil 4 mg with a prophylactic phenylephrine infusion or a placebo infusion. An i.v. bolus of oxytocin 5 u (Syntocinon, Novartis, Copenhagen, Denmark) was injected into a rapidly running i.v. line immediately after delivery. Twenty women required a second bolus of oxytocin 5 u. Ten of these women were given 7 mg and 10 were given 10 mg of spinal bupivacaine. Baseline haemodynamic measurement was defined as the mean value during the last 30 s before the injection of oxytocin. The differences in maximal haemodynamic changes of the first and the second doses in these 20 patients were analysed using SPSS statistical program version 15.0 (Statistical Package for Social Sciences Inc., Chicago, IL, USA) by paired t-test. Bonferroni's correction (P/K; K, number of analyses) was performed to avoid type I error due to multiple outcome analyses. Hence, P-values ,0.0125 (K¼4) were regarded as statistically significant in the analyses of CO, SV, systolic arterial pressure (SAP), and SVR.
The haemodynamic data from each patient were downloaded as csv-files from the LiDCOplus-monitor. Construction of the data set was done using MatLab version R2007a (The MathWorks, Natick, MA, USA), where the beat-to-beat values were computed into average values every 10 s.
Results
Twenty women needed two doses of oxytocin 5 u. The haemodynamic effects of the first and second doses were clinically and statistically different from baseline (Fig. 1) . The haemodynamic changes after the first dose were more prominent than after the second dose of oxytocin. Table 1 shows the haemodynamic changes for CO, SAP, SVR, and SV after the first and second doses of oxytocin, including P-values for the paired t-test. Mean CO increased from 7.2 to 13.8 litre min 21 after the first dose and from 6.9 to 9.8 litre min 21 after the second dose. Baseline was defined as the mean value during the last 30 s before the injection of oxytocin. When administering the second dose of oxytocin, the baseline was lower for SAP and for SVR. The mean time interval between the first and the second doses of oxytocin was 376 s (range 105-1009).
There were minor, and non-significant, differences in bleeding (495 vs 450 ml) and haemoglobin decrease (1.0 vs 0.7 g dl 21 ) in these 20 patients compared with the other 60 patients in the study. Nine patients were given misoprostol 400 mg rectally, three patients had an infusion of oxytocin after delivery, and one patient had an intramyometrial injection of prostinfenem.
Discussion
Our data demonstrate the haemodynamic effects of oxytocin 5 u i.v. in healthy parturients during Caesarean section, confirming the results from previously published trials. 2 -4 Our findings also demonstrate that a second dose of i.v oxytocin 5 u given on average 6 min after delivery produced clinically significant haemodynamic effects in the same direction as the first dose, but the effects are statistically significantly smaller than after the first dose. A recently published study giving oxytocin 10 u showed the same magnitude of haemodynamic effects in non-pregnant women as in pregnant women during Caesarean section. 9 This documents that the circulatory changes of oxytocin after delivery really are caused by oxytocin, and are not due to the delivery itself as stated by some authors. 10 Delivery may contribute to the circulatory changes, but the main effects are due to oxytocin. This was demonstrated by Thomas and colleagues 3 comparing a bolus of oxytocin with an infusion. To examine the effect of delivery itself, one must design a study in which the oxytocin injection is delayed some minutes after delivery of the baby. An implication of the findings reported here is that administration of oxytocin 5 u as a bolus should probably be abandoned since the large haemodynamic effects could be dangerous to vulnerable parturients. An infusion, or smaller repeated doses, might be a better choice. The reduced effects of a second-dose oxytocin could be due to a decrease in endothelial receptor sensitivity. Desensitization of uterine oxytocin receptors has been described after continuous oxytocin infusion. 11 Oxytocin-induced desensitization is concentrationdependent and is characterized by a reduction in the number of oxytocin binding sites on intact myometrial cells. Our findings of a clinically significant decrease in haemodynamic effects after a second oxytocin injection could indicate a concomitant desensitization of endothelial oxytocin receptors. The mean time interval between the two doses of oxytocin was 6 min. The half-life of oxytocin is 5 -12 min. 12 This implies that half of the first dose is still present when the second dose is given, and could be part of the explanation for the observed reduced effect of a repeated dose of oxytocin. Assessment of uterine tone is difficult to quantify and it may be relevant to question the practice of giving a repeated bolus of oxytocin. On the basis of current evidence, it might be justified to change medication instead of giving a second dose of oxytocin. Phaneuf and colleagues 13 have shown that oxytocin-induced desensitization does not affect the response to other agonists such as prostaglandins. In our department, we give misoprostol, a synthetic prostaglandin analogue, rectally (Cytotec, Pfizer, NY, USA).
In conclusion, this study confirms the haemodynamic effects after two repeated doses of oxytocin. The haemodynamic changes after the second dose are smaller compared with the first dose of oxytocin.
